Inventor · disambiguated record

Venkat R. Thalladi

Also filed as: THALLADI VENKAT · THALLADI VENKAT R

43 granted patents·5 pending applications·133 citations·filing 2006–2024

97Inventor score

Technology areasA61P C07D A61K C07B C07C

Files withTHERAVANCE BIOPHARMA R&D IP LLC36 COLSON PIERRE-JEAN3 THALLADI VENKAT R2 WORCESTER POLYTECH INST2 FATHEREE PAUL R1

Top patents by PatentIndex Score

48 records

0197US10183942B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Jan 22, 2019·23 cites·6 claims
0296US11780852B2Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrileTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Oct 10, 2023·3 cites·55 claims
0396US10493077B2Fused imidazo-piperidine JAK inhibitor compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Dec 3, 2019·14 cites·19 claims
0495US10251874B2Crystalline forms of a JAK inhibitor compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Apr 9, 2019·23 cites·23 claims
0594US10913740B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Feb 9, 2021·5 cites·18 claims
0693US11230536B2Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereofTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Jan 25, 2022·2 cites·20 claims
0792US10947254B2Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrileTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Mar 16, 2021·3 cites·56 claims
0892US10072026B2Crystalline form of 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrileTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Sep 11, 2018·7 cites·19 claims
0991US9533962B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Jan 3, 2017·6 cites·28 claims
1089US11718591B2Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereofTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Aug 8, 2023·1 cites·20 claims
1189US9872855B2(2R,4R)-5-(5′-Chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Jan 23, 2018·5 cites·9 claims
1288US11033533B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Jun 15, 2021·1 cites·20 claims
1387US11160800B2Methods of treatment using a JAK inhibitor compoundTHERAVANCE BIOPHARMA R & D IP LLC·Filed 2019·Granted Nov 2, 2021·3 cites·20 claims
1487US10538513B2Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Jan 21, 2020·4 cites·16 claims
1587US10472335B2Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-bipheny]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereofTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Nov 12, 2019·4 cites·15 claims
1687US10172834B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Jan 8, 2019·3 cites·3 claims
1787US10100021B2Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereofTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Oct 16, 2018·4 cites·24 claims
1886US10752599B2Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereofTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Aug 25, 2020·3 cites·20 claims
1985US12351561B2Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereofTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2024·Granted Jul 8, 2025·0 cites·63 claims
2085US10392368B2Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Aug 27, 2019·5 cites·46 claims
2184US10548879B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Feb 4, 2020·2 cites·20 claims
2284US10494382B2Crystalline solvate comprising 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile, methanol, N-N-dimethylformamide, and waterTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Dec 3, 2019·2 cites·10 claims
2383US10968205B2Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Apr 6, 2021·1 cites·26 claims
2483US8399513B2Levodopa prodrug mesylate hydrateKARABORNI SAMI·Filed 2009·Granted Mar 19, 2013·4 cites·24 claims
2582US11160810B2Fused imidazo-piperidine JAK inhibitor compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Nov 2, 2021·2 cites·27 claims
2679US11718616B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2022·Granted Aug 8, 2023·0 cites·7 claims
2779US11642332B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted May 9, 2023·0 cites·20 claims
2877US8362060B2Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acidTHERAVANCE INC·Filed 2011·Granted Jan 29, 2013·2 cites·26 claims
2975US10369142B2Combination dosage form of a mu opioid receptor antagonist and an opioid agentTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Aug 6, 2019·1 cites·9 claims
3074US10946009B2Combination dosage form of a mu opioid receptor antagonist and an opioid agentTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Mar 16, 2021·0 cites·14 claims
3172US11452723B2Combination dosage form of a mu opioid receptor antagonist and an opioid agentTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Sep 27, 2022·0 cites·11 claims
3270US2022119369A1Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Application pending·0 cites
3368US9249105B2Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acidFATHEREE PAUL R·Filed 2014·Granted Feb 2, 2016·0 cites·7 claims
3462US8722733B2Levodopa prodrug mesylate hydrateXENOPORT INC·Filed 2013·Granted May 13, 2014·0 cites·19 claims
3560US9868698B2(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Jan 16, 2018·0 cites·2 claims
3657US9433598B2(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Sep 6, 2016·0 cites·26 claims
3756US9670143B2(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxmethyl-2-methylpentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Jun 6, 2017·0 cites·2 claims
3855US8969403B2Crystalline forms of a 3-[2-methanesulfonyl-1-(4-trifluoromethyl-phenoxy)ethyl]pyrrolidine compoundCOLSON PIERRE-JEAN·Filed 2014·Granted Mar 3, 2015·0 cites·4 claims
3953US8658691B2Crystalline forms of a 3-[2-methanesulfonyl-1-(4-trifluoromethyl-phenoxy)ethyl]pyrrolidine compoundCOLSON PIERRE-JEAN·Filed 2012·Granted Feb 25, 2014·0 cites·3 claims
4052US11795180B2Formulation of a pan-JAK inhibitorTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Oct 24, 2023·0 cites·24 claims
4152US2016287573A1Combination dosage form of a mu opioid receptor antagonist and an opioid agentTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Application pending·0 cites
4249US2022306626A1Crystalline form of a dihydrochloride salt of a jak inhibitor compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2022·Application pending·0 cites
4347US7935309B2Multi-transduction mechanism based microfluidic analyte sensorsWORCESTER POLYTECH INST·Filed 2006·Granted May 3, 2011·0 cites·16 claims
4447US2011009623A1Selective growth of stable polymorphsWORCESTER POLYTECH INST·Filed 2007·Application pending·0 cites
4545US8883135B2Crystalline form of a pyridyl-piperazinyl hepatitis C virus inhibitorTHALLADI VENKAT R·Filed 2013·Granted Nov 11, 2014·0 cites·27 claims
4641US8697724B2Crystalline oxalate salts of a diamide compoundRAPTA MIROSLAV·Filed 2011·Granted Apr 15, 2014·0 cites·34 claims
4741US2015141483A1Crystalline forms of a 3-[2-methanesulfonyl-1-(4-trifluoromethyl-phenoxy)ethyl]pyrrolidine compoundCOLSON PIERRE-JEAN·Filed 2015·Application pending·0 cites
4840US9271965B2Crystalline forms of (R)-3-[N-(3'-chlorobiphenyl-4-ylmethyl)-N'-(3-hydroxyisoxazole-5-carbonyl)hydrazino]-2-hydroxyproprionic acid isopropyl esterTHALLADI VENKAT R·Filed 2013·Granted Mar 1, 2016·0 cites·46 claims

Join the waitlist — get patent alerts

Get an alert when Venkat R. Thalladi files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →